Chen Jyh-Ping, Yang Pei-Chin, Ma Yunn-Hwa, Lu Yu-Jen
Department of Chemical and Materials Engineering, Chang Gung University Kwei-San, Taoyuan 333, Taiwan, ROC.
J Nanosci Nanotechnol. 2011 Dec;11(12):11089-94. doi: 10.1166/jnn.2011.3953.
Magnetic nanoparticle (MNP) modified by carboxymethyl dextran (CMD) was synthesized and characterized by Fourier transform infrared spectroscopy, transmission electron microscopy, superconducting quantum interference device, dynamic light-scattering, thermogravimetric analysis, and X-ray diffraction. CMD coating on the particle surface provides abundant -COOH functional groups for conjugating with a thrombolytic drug, recombinant tissue plasminogen activator (rtPA). CMD-coated MNP (CMD-MNP) prepared with higher CMD/MNP ratios had higher CMD content, less iron content, more -COOH surface groups, smaller hydrodynamic diameter, and smaller saturation magnetization. The in vitro biocompatibility study using lactate dehydrogenase assays indicated that CMD-MNP elicited no cell cytotoxicity. The optimum drug loading could be achieved by contacting 0.25 mg rtPA with 5 mg CMD-MNP where all rtPA is immobilized to the magnetic nanocarrier with full retention of its thrombolytic activity.
合成了羧甲基葡聚糖（CMD）修饰的磁性纳米颗粒（MNP），并通过傅里叶变换红外光谱、透射电子显微镜、超导量子干涉仪、动态光散射、热重分析和X射线衍射对其进行了表征。颗粒表面的CMD涂层为与溶栓药物重组组织型纤溶酶原激活剂（rtPA）结合提供了丰富的-COOH官能团。以较高的CMD/MNP比例制备的CMD包被的MNP（CMD-MNP）具有更高的CMD含量、更低的铁含量、更多的-COOH表面基团、更小的流体动力学直径和更小的饱和磁化强度。使用乳酸脱氢酶测定法进行的体外生物相容性研究表明，CMD-MNP没有引起细胞毒性。通过使0.25mg rtPA与5mg CMD-MNP接触可实现最佳载药量，其中所有rtPA都固定在磁性纳米载体上，其溶栓活性完全保留。
